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Abstract
Background: It is unknown if survival prediction tools (SPTs) sufficiently predict survival in patients who undergo
palliative reirradiation of spinal metastases. We therefore set out to clarify if SPTs can predict survival in this patient
population.
Methods: We retrospectively analyzed spinal reirradiations performed (n = 58, 52 patients, 44 included in analysis).
SPTs for patients with spinal metastases were identified and compared to a general palliative score and to a dedicated
SPT to estimate prognosis in palliative reirradiation independent of site (SPT-Nieder).
Results: Consistently in all tests, SPT-Nieder showed best predictive performance as compared to other tools. Items
associated with survival were general condition (KPS), liver metastases, and steroid use. Other factors like primary tumor
site, pleural effusion, and bone metastases were not correlated with survival. We adapted an own score to the data
which performed comparable to SPT-Nieder but avoids the pleural effusion item. Both scores showed good
performance in identifying long-term survivors with late recurrences.
Conclusions: Survival prediction in case of spinal reirradiation is possible with sufficient predictive separation.
Applying SPTs in case of reirradiation helps to identify patients with good life expectancy who might benefit
from dose escalation or longer treatment courses.
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Background
Survival from most types of cancer has increased steadily
during the last years in developed countries [1]. Longer
survival time is associated with an increased number
of patients who live long enough to experience a re-
currence after an initial radiotherapy [2]. Currently
around 8–20 % of patients with bone metastases receive
reirradiation [3]. Although reirradiation is possible with
modern techniques, it can be associated with an increased
risk of side effects, depending on reirradiation site, vol-
ume, cumulative dose, fraction dose, and interval between
irradiation and reirradiation [4–6]. Due to potentially de-
bilitating side effects such as radiation myelopathy (RM)
or radiation-induced sacral (plexus) neuropathy [7–9],
historically only few studies of conventional reirradiation
of spinal metastases have been reported [7, 10–12]. A
retrospective analysis of cases treated at the Mayo Clinic
between 1975 and 1992 showed that 5 out of 54 patients
developed neurologic deterioration after reirradiation. Al-
though only one of them developed the typical Brown-
Sequard syndrome, the authors could not determine if the
other four patients had delayed RM, or if symptoms were
triggered by spinal cord compression. Median time of
onset for deterioration was 7.8 months, and median sur-
vival of all patients was 4.2 months, therefore it is possible
that the number would have been higher, had patients
survived longer [7]. Introduction of modern techniques
such as Intensity Modulated Radiation Therapy (IMRT)
or Stereotactic Body Radiation Therapy (SBRT) changed
the approaches to reirradiation of paraspinal tumors
profoundly. Today, as reviewed by Kirkpatrick et al. [13],
multiple series on reirradiation of the spinal cord have
been reported with low, albeit not completely absent risk
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of RM. The residual risk of RM in primary SBRT or re-
SBRT has been primarily attributed to higher doses per
fraction [14]. On the other hand, new treatment concepts
such as multiple ablative treatments in patients with oligo-
metastatic disease warrant higher doses to obtain suffi-
cient tumor control [15]. If patients benefit from longer,
potentially more wearisome radiation courses, depends
mainly on their life expectancy. It is unknown if available
survival prediction tools (SPTs) can be applied to accur-
ately predict survival in patients who are eligible for reirra-
diation of spinal metastases.
This study intends to validate available approaches/
instruments to predict survival in a patient group who
underwent reirradiation for spinal metastases in a single
institution.
Patients and methods
From November 2006 to July 2013, 58 spinal metastases
were reirradiated in 52 patients. If a patient received a
second reirradiation (n = 7), only the first reirradiation
was included in further analysis. Three patients were
excluded because they had received radiotherapy due to
hematologic malignancies, or spinal ependymoma. Add-
itionally, 4 patients were excluded because of missing
data. The remaining patients (n = 44) were included in
further analysis. Patient characteristics are detailed in
Table 1. The study was approved by the ethics commit-
tee of Heidelberg University, Medical Faculty Mannheim
(2013-602N-MA).
Survival scores were identified by a literature search
using PubMed with the following search terms: Spinal
[OR] Spine [AND] Metastases Survival Score. Instruments
designed for specific cancer entities [16] or for patients
who already had spinal cord compression [17, 18] were
excluded. SPTs which evaluated other outcomes than
survival [2] were also excluded. Studies detailing SPTs that
did not provide a numerical score to rank patients accord-
ing to risk were transformed into such a scoring system,
e.g. subgroups of “favorable, moderate, and unfavorable”
were transformed into numerical values to facilitate non-
parametric analysis. If such transformation was not
reasonably possible, SPTs were excluded [19]. In addition
to spine-specific scores, we included the SPT as developed
by Chow et al. [20, 21] (SPT-Chow). SPT-Chow was
chosen because it is a simple and validated tool, widely
applicable in palliative settings [22]. Furthermore, we
included the SPT developed for reirradiation in general by
Nieder et al. [23]. SPTs as developed by Tokuhashi [24],
Balain [25], Bauer [26], Bollen [27], and Tomita et al. [28],
were deemed appropriate. Balain et al. called their tool the
Oswestry risk index (SPT-Oswestry). All other SPTs were
named according to the 1st author of the article describing
the index. All details on the SPTs are summarized in
Additional file 1: Table S1. Each SPT was then applied to
each patient, thereby assigning all patients to prognostic
groups as defined by each SPT. We used different ap-
proaches to validate each prognostic model. First, we
calculated a simple index of separation (PSEP), as defined
by Altman et al. [29]. Basically, PSEP is the difference
between Pworst, and Pbest, which is the difference of the
probability of dying in the group with the worst prognosis,
and the group with the best prognosis. As described previ-
ously [21], we calculated PSEP at 3, 6, and 12 months after
start of reirradiation.
Prognostic separation was also evaluated using the
D-index, as developed by Royston and Sauerbrei [30].
The D-index can be interpreted as a robust version of
the hazard ratio (HR) with 1 representing the null case,
i.e. a difference in predicted survival does not result in a
different observed survival. In the original article, it was
reported as the logarithm of the HR (log-HR; 0 represent-
ing the null case) [30]. Different D-indices were compared
using Student’s t-test as described [31]. Discrimination
(i.e. the ability of a model to correctly rank the patients by
risk), was evaluated by calculating the Concordance-Index
“C” as proposed by Harrell et al. [32]. C-index is an appli-
cation of Somers’ D and gives the probability that for a
randomly chosen pair of patients, the predicted and the
observed outcomes are concordant. A value of 0.5 indi-
cates no predictive discrimination (i.e. the null case), and
1.0 indicates perfect separation of patients with different
outcomes [21, 32, 33]. Different C-indices were compared
as described by Kang et al. [34].
Finally we assessed the impact of each item with a Cox
model, calculating the (Pseudo-)R2-coefficient according
to Cox and Snell [35]. We included only items into
multivariate modeling that were correlated with survival
in univariate Kaplan-Meier models with a significance
level of p ≤ 0.05 (Mantel-Cox log-rank). All statistics were
calculated using R, a language and environment for statis-
tical computing that is available for free online [31, 36].
Survival graphs, were prepared using SPSS Version 15
(SPSS Inc., Chicago IL).
Results
All reirradiations were applied as fractionated IMRTs.
Median total dose was 30 Gy (10–45 Gy), delivered
in 2 Gy fractions (range: 1.8–3.0 Gy). Reirradiation
was discontinued in 4 patients due to worsening of
general condition (n = 3) and death (n = 1). After a median
follow-up of 36.2 months, 37 patients (84.1 %) had died.
Median survival was 9 months after start of reirradiation
(see Fig. 1a). Five patients (11.4 %) died within one month
after their last fraction of reirradiation. We observed no
case of RM or other severe late toxicities. One patient
developed new sensory symptoms within 3 days after
reirradiation but MRI showed no signs of RM, and symp-
toms resolved without intervention. Tumor control was
Buergy et al. Radiation Oncology  (2016) 11:35 Page 2 of 7
acceptable with 9 patients (20.5 %) developing local recur-
rences (LR). LR occurred at a median time of 12.2 months
after initiation of reirradiation. Two cases of early recur-
rence within 3 months were observed, both were accom-
panied by rapid systemic tumor progression and death
within 5 months. Local control (LC) as defined by diag-
nostic imaging or clinical examination was maintained
until death or end of follow-up in 29 patients (65.9 %). LC
was undetermined in 6 patients (13.6 %), including one
patient who died during reirradiation and 2 patients who
discontinued reirradiation.
Patients were classified into predictive groups as de-
scribed by each SPT. SPT-Nieder contains a pleural
effusion (PE) item and a steroid use item (see Additional
file 1: Table S1). Scores of patients with unknown pleural
status were assigned to the group with no PE, i.e. no
routine thorax imaging was performed when PE was not
suspected. The same applies to the steroid usage item: in
some patients (timing of) steroid use was not specifically
documented, these patients were assigned to the group
without steroid use. To avoid bias, we re-calculated all
SPT-Nieder results after excluding all patients with un-
known pleural status, or specific documentation of steroid
use (n = 11). As detailed below, this did not change results
significantly. PSEP showed good prognostic separation, at
months 3, 6, and 12 using SPT-Nieder (73.3–86.7 %).
Good late separation after 12 months was also obtained
applying SPT-Chow (70 %), and SPT-Tokuhashi (64 %),
however both SPTs showed weak early results in months
3 and 6. All other SPTs showed insufficient separation as
measured by PSEP (see Table 2). Calculation of C-indices
showed that reasonable separation of prognostic groups
can be obtained using SPT-Nieder (C = 0.68, p < 0.001).
Results were similar, if patients with unknown pleural
Table 1 Patient characteristics of patients who received spinal
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Number of extraspinal bone
metastases
n = 0 13
n = 1 13
n = 2 4
n≥ 3 14
Visceral metastases No 18
Yes 26
Potentially removable 6
Liver metastases No 35
Yes 9
Lung metastases No 34
Yes 10
Brain metastases No 40
Yes 4










Age at start of reirradiation Median (range) 67 (39–88)
Table 1 Patient characteristics of patients who received spinal
reirradiation (n = 44) (Continued)
KPS at start [end] of reirradiation Median 70 [70]
Range 30–100
[20–100]
Site of reirradiation [site of
first irradiation]
Cervical spine 1 [3]
Cervical and thoracic spine 5 [4]
Thoracic spine 14 [14]
Thoracic and lumbar spine 6 [5]
Lumbar spine 10 [10]
Lumbar spine and os
sacrum
4 [6]
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status were excluded (C = 0.7, p < 0.001). SPT-Tokuhashi,
SPT-Bollen, SPT-Tomita, and SPT-Chow also showed
significant but numerically worse prognostic separation
(C = 0.64, C = 0.63, C = 0.6, and C = 0.6, all p < 0.05). C-
indices of SPT-Bauer and SPT-Oswestry did not differ
significantly from the null case. Results obtained by calcu-
lation of D-indices demonstrated that actual risk of dying
in our patient sample during follow-up was predicted by
SPT-Tokuhashi (D = 0.61, p = 0.03, estimated HR = 1.84),
SPT-Chow (D = 0.66, p = 0.04, estimated HR = 1.94), and
SPT-Nieder (D = 1.1, p < 0.001; estimated HR = 3.02). All
other scoring systems were not statistically different from
the null case. If compared directly with the other scoring
systems, SPT-Nieder showed significantly better prognos-
tic discrimination as compared to all indices besides SPT-
Tokuhashi and SPT-Chow (p = 0.1 and p = 0.11). Survival
curves of all SPTs that showed acceptable results in PSEP,
C-index, and D-index are shown in Fig. 1, i.e. SPT-Chow
(b), SPT-Tokuhashi (c), SPT-Nieder (d). All other survival
curves are shown in Additional file 2: Figure S1b-e.
If patients with unknown PE and steroid use were
excluded, SPT-Nieder performed numerically better
(D = 1.43, p < 0.001; estimated HR = 4.17) and consist-
ently showed significantly better prognostic separation if
directly compared to all other SPTs (p < 0.05) besides
SPT-Tokuhashi (p = 0.06); see Additional file 2: Figure S1a
for survival curve. To examine which items contributed to
the performance of SPTs, we analyzed each item of each
instrument in univariate survival functions. If patients had
liver metastases, they died significantly earlier (p = 0.006,
Fig. 1 Survival curves are shown for all patients in (a), median OS in all patients was 9 months. b-d show survival curves in patients assigned to
risk groups as detailed in each SPT that showed prognostic separation as measured by PSEP, C-index, and D-index. Median OS in the following
legend is ranked from best to worst predictive group. b Chow, median OS: 13.9/4.6/3.2 months, p = 0.11. c Tokuhashi, median OS: 33/12.1/3.7
months, p = 0.033. d Nieder, median OS: 24.1/6/3.2/1.2 months, p < 0.001; § = patients with unknown PE and steroid use ranked as no PE and no
steroid use
Table 2 PSEP results after 3, 6, and 12 months
SPT PSEP at 3 months PSEP at 6 months PSEP at 12 months
Bollen 15 % 15 % 35 %
Tomita 26.7 % 28.9 % 40 %
Bauer <0 % <0 % 4.4 %
Chow 13.3 % 25 % 70 %
Tokuhashi 35.3 % 46.3 % 64 %
Niedera 86.7 % 86.7 % 73.3 %
Niederb 90 % 90 % 70 %
Niedera: Patients with unknown pleural status were assigned to the group
without pleural effusion
Niederb: Patients with unknown pleural status were excluded
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median survival 13 vs. 3.2 months). Visceral metastases in
general were not significantly associated with survival.
Further classification into removable vs. non-removable
metastases also did not show a significant survival advan-
tage for patients with removable vs. unremovable metasta-
ses. Karnofsky Performance Status (KPS) was significantly
associated with survival (p < 0.001, median survival times
depended on cut-off values). Steroid use was also associ-
ated with worse outcome (p = 0.028, median survival 13.6
vs. 3.1 months, significance was maintained after exclu-
sion of all patients with undocumented steroid use: p =
0.038). All other items, including primary tumor site were
not significantly associated with survival. Based on these
observations, we adapted a new score to our collective.
Basically this new SPT is similar to SPT-Nieder but has
only three items: KPS (10–70 % vs. 80–100 %), liver
metastases (yes vs. no), and steroid use (yes vs. no). In the
Cox model it showed higher R2 (0.248 vs. 0.237; max
possible 0.994 in both cases), comparison of D- and C-
indices did not show significant differences as compared
to SPT-Nieder (see Additional file 2: Figure S1f for
survival curve).
Discussion
In a recent survey [37], radiation oncologists reported to
assess life expectancy in 91 % of their palliative patient
evaluations. Their estimates were inaccurately optimistic
with an overestimation of survival in 67 % of cases [37]
which is in line with other physician’s survival estimates
in palliative cancer care [38–40]. Predicting survival in
the setting of reirradiation might be even more difficult.
Patient samples are inhomogeneous, and as indicated by
the historical Mayo Clinic series [7], and reproduced in
our study, there is a wide range of observed survival times
(historical series: 1–51 months vs. 0.5–79(+) months in
our series). Except for SPT-Tokuhashi, SPTs developed
to estimate survival after primary treatment of spinal
metastases showed worse performance as compared to
SPT-Nieder. The same was true for the well established
SPT-Chow which is generally accepted as a valid
survival tool in palliative cancer care [20–22]. On the
other hand, SPT-Nieder which was developed in a small
(n = 87), inhomogeneous patient sample including reir-
radiations for brain, bone, and lung metastases, as well
as primary tumors, among others [23], showed accept-
able predictive separation.
Detailed analysis of all items of the different scores,
and of other patient parameters showed that SPT-Nieder
included all items that were significantly associated with
survival in our patient group, i.e. general condition, liver
metastases, and steroid usage. Pleural effusion was the
only item in SPT-Nieder that was not associated with
survival in our collective. Nevertheless, we recommend
to use SPT-Nieder without modification, until there is
confirmation in an independent collective, that the PE
item can be eliminated without loss of predictive accuracy.
Consistent with Nieder’s observations, primary tumor site
had no impact on survival in our patients. We emphasize
that this item should be avoided as it seems to have
limited accuracy in situations in which patients with
aggressive tumors already lived longer than expected to
experience in-field recurrence. Furthermore, new therap-
ies, such as immunotherapeutic approaches might pro-
foundly change prognosis in primary tumors traditionally
considered to confer worse prognosis. Survival prediction
is especially relevant in patients who live long enough
to experience local recurrence and may require dose
escalation. Interestingly, of 6 patients who developed
late recurrences (11–59 months), SPT-Nieder would
have ranked 4 in the best, and two in the second best
(of 4) prognostic group. A potential score incorporat-
ing liver metastases, KPS, and steroid usage, which
excludes the PE item would have assigned 5 patients
to the long-term survivor group, and 1 patient to the
second best group (of 4). All other scores ranked at
least one long-term survivor in worst or second worst
prognostic group. These results indicate that long-
term survivors at risk for late recurrences who might
benefit from dose escalation might be identified with
appropriate prediction tools.
It is reassuring that despite the heterogeneous group
of patients, the only survival tool which was developed
for general reirradiation purposes worked best in our
patient group. Our study has several shortcomings, it is
a retrospective analysis in a small patient collective. Like
other studies which include only patients who actually
received radiotherapy, our study has an exclusion bias,
i.e. patients who were not fit enough to undergo radio-
therapy were not included in any analysis. This explains
the low number of patients in worst prognostic groups,
although many patients had late stage disease. Radiation
therapy regimens in our study reflected clinical decisions
involving estimated life expectancy, and other factors,
but none of the SPTs were used at that time in our prac-
tice. Five patients (~11.4 %) in our study received some
fractions of reirradiation during their last month of life.
If radiotherapy at end of life should be completely
avoided is controversial, however, single fraction or
short course treatments should be preferred. A rate
of 11 % irradiations during the last month of life
might indicate overoptimistic clinical expectations as
described previously [37].
Conclusion
Taken together, predicting survival in patients who
undergo palliative reirradiation for spinal metastases
is possible with acceptable discrimination. SPT-Nieder
showed best prognostic accuracy, although the pleural
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effusion item did not correlate with survival in our group.
Radiation oncologists typically estimate survival using
performance status, overall metastatic burden, presence of
central nervous system metastases, and primary cancer
site [37]. Our data indicate that this approach should be
reconsidered when it comes to reirradiation of spinal me-
tastases: typical predictive factors such as primary tumor,
central nervous system metastases, and overall metastatic
burden may have limited efficacy as compared to KPS,
liver metastases, and steroid use.
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Additional file 1: Table S1. All items that contribute to each SPT are
shown and ranked according to the risk that has been assigned to each
item by the authors of each SPT. (PDF 166 kb)
Additional file 2: Figure S1. Survival curves in patients assigned to risk
groups as detailed in SPT-Nieder (# = excluding all patients with unknown
pleural status, and steroid use), SPT-Bollen, SPT-Tomita, SPT-Oswestry,
and SPT-Bauer are shown in a-e. Figure S2f. shows performance of risk
groups when ranked according to a score that was specifically adapted
to the collective but has not yet been validated in an independent
patient group. Median OS in the following legend is ranked from best
to worst predictive group. a) Nieder, median OS: 21.8/4.6/3.1/1.2 months,
p < 0.001; # = patients with unknown PE and unknown steroid use
excluded. b) Bollen, median OS: 13/14.9/3.8/7.9 months, p = 0.12.
c) Tomita, median OS: 20.1/2.2/7.9/3.8 months, p = 0.35. d) Oswestry,
median OS: 14.9/6/3.1/3.8/29.1, p = 0.1 months. e) Bauer, median
OS: 13/7.9/24.1 months, p = 0.75. f) Specifically adapted SPT, median
OS: 24.1/8.97/3.2/1.84 months, p < 0.001 (TIF 4362 kb)
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